Compare AbbVie Inc (ABBV) vs Illumina, Inc. (ILMN) Price & Performance

AbbVie (ABBV) trades at $264.00, up 0.54% on the day, with a bullish technical signal and strong analyst consensus. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.65 surpassing the $3.61 estimate. Revenue growth is robust, reaching $61.16 billion in 2025, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines. The company maintains a high gross profit margin of 71.48% and offers a solid dividend, with recent payouts of $1.73 per share.

Outlook remains positive with a consensus price target of $287.08, implying ~9% upside. Key opportunities include pipeline strength in oncology and sustained immunology growth. Risks involve high debt levels, patent expirations in the 2030s, and regulatory pressures. The stock is well-positioned for growth but requires monitoring of execution on new drug launches and debt management.

Illumina (ILMN) trades at $239.62, up 4.67% today, showing strong momentum with three consecutive quarterly EPS beats. The stock exhibits bullish technical signals with moving averages supporting upward trends and key resistance at $250. Fundamentally, the company has returned to profitability with $850M net income in 2025 after previous losses, supported by 66.4% gross margins and robust cash flow generation of $1.08B from operations. Recent S&P 500 inclusion announcement has boosted investor interest.

ILMN presents a growth opportunity with improving profitability and positive analyst sentiment (54% buy ratings), though valuation remains elevated at P/E of 45.7. Key risks include competitive pressures in genomics and execution challenges in maintaining margin expansion. The consensus price target of $210.67 suggests potential downside from current levels despite recent momentum.